Canola Oil

Why It Matters for Longevity

Canola oil's case for inclusion in a longevity diet rests on three properties: it is the most accessible culinary source of plant-based omega-3 ALA; it has one of the lowest saturated fat contents of common cooking oils (~7%); and it has a high smoke point (~204°C), making it suitable for cooking at temperatures where unfiltered olive oil would begin to degrade.

ALA (alpha-linolenic acid, 9.1 g per 100 g) is an essential omega-3 fatty acid the body cannot synthesize. While conversion to the long-chain EPA and DHA is limited (~5–10% to EPA, less than 0.5% to DHA), dietary ALA has independent effects on cardiovascular endpoints through mechanisms that are partially distinct from those of EPA and DHA — including incorporation into membrane phospholipids, modulation of eicosanoid precursor pools, and reduction of platelet aggregation.

High-oleic rapeseed (canola) and flaxseed oils modulated serum lipids and reduced inflammatory biomarkers in a controlled trial, with canola oil demonstrating a favorable MUFA:PUFA profile supporting cardiovascular protection (Gillingham et al., 2011, Br J Nutr). Higher intakes of omega-3 fatty acids reduced major cardiovascular events by 25% in the REDUCE-IT trial, establishing a mechanistic basis for omega-3 intake in cardiovascular longevity protocols (Bhatt et al., 2019, N Engl J Med). A dietary analysis of US diet-mortality associations found that higher intake of polyunsaturated fat as a replacement for saturated fat was among the strongest dietary predictors of reduced cardiovascular mortality (Micha et al., 2017, JAMA).

LDL Reduction: Evidence from Controlled Trials

A systematic review and meta-analysis that searched the literature through January 2020 and pooled 42 controlled clinical trials found that canola oil significantly reduced LDL cholesterol by −0.23 mmol/L (approximately −8.9 mg/dL) compared with other edible oils. Total cholesterol fell by −0.27 mmol/L across 37 trials and apolipoprotein B by −0.03 g/L across 14 trials. When compared specifically against saturated fats, the LDL reduction widened to −0.49 mmol/L. The dose-response analysis identified that replacing approximately 15% of total caloric intake with canola oil provided the greatest LDL benefit, and effects were most consistent when canola oil was consumed for longer than 30 days (Amiri et al., 2020, Nutr Metab Cardiovasc Dis).

An earlier meta-analysis of 27 RCTs involving 1,359 participants found that canola oil lowered LDL cholesterol by 6.4 mg/dL (95% CI −10.8 to −2.0) and total cholesterol by 7.24 mg/dL (95% CI −12.1 to −2.7) versus comparator oils, with benefits more pronounced in participants over 50 years of age (Ghobadi et al., 2019, J Am Coll Nutr). The mechanism is straightforward: oleic acid (MUFA, ~61% of canola oil) reduces LDL cholesterol by downregulating hepatic PCSK9 expression and upregulating LDL receptor activity, while ALA contributes through a complementary pathway involving reduced hepatic TG synthesis.

ALA and All-Cause Mortality: Population Evidence

A dose-response meta-analysis of 41 prospective cohort studies totaling 1,197,564 participants and 198,113 deaths found that higher dietary ALA intake was associated with meaningfully lower mortality. Comparing highest versus lowest ALA intake categories, all-cause mortality was reduced by 10% (RR 0.90; 95% CI 0.83–0.97), CVD mortality by 8% (RR 0.92; 95% CI 0.86–0.99), and coronary heart disease mortality by 11% (RR 0.89; 95% CI 0.81–0.97). Dose-response modeling showed that each 1 g/day increment in ALA intake — equivalent to approximately one tablespoon of canola oil or half an ounce of walnuts — was associated with a 5% lower risk of both all-cause and CVD mortality (Naghshi et al., 2021, BMJ). The median ALA intake in the highest quintile of most studies was above 1.6 g/day, a level easily reached with one to two tablespoons of canola oil daily.

Glycemic Effects: Evidence in Type 2 Diabetes

A parallel-design RCT in 141 adults with type 2 diabetes managed on oral medications tested a canola oil-enriched low-glycemic-load diet against a whole-grain control over three months. The canola oil arm achieved a significantly greater reduction in HbA1c: −0.47 percentage points versus −0.31 in the control (P = 0.002), with the benefit most pronounced in participants with elevated baseline systolic blood pressure. The canola oil diet also produced a greater reduction in calculated Framingham cardiovascular risk score (Jenkins et al., 2014, Diabetes Care). The glycemic benefit likely reflects canola oil's oleic acid improving insulin receptor signaling and reducing hepatic glucose output, mechanisms that have been characterized in controlled feeding studies.

Oleic Acid, Oxidative Stability, and Cooking Safety

Oleic acid (MUFA) is more resistant to oxidative degradation under heat than the polyunsaturated linoleic acid (LA) that predominates in corn, soybean, and sunflower oils. When heated, PUFAs oxidize at a faster rate, generating aldehydes and cyclic fatty acid monomers that are absorbed and have been associated with cellular toxicity in animal models. Canola oil's oleic acid content (~61%) gives it substantially better thermal stability than high-PUFA oils, though markedly lower thermal stability than high-oleic sunflower or avocado oil. In practical terms, canola oil is appropriate for stovetop sauteing and baking; sustained deep-frying above 180°C over multiple cycles is a different context where all unsaturated oils perform poorly compared to more saturated fats.

Modern canola varieties are specifically bred to contain less than 2% erucic acid as a share of total fatty acids — well below the historical rapeseed content of 20–45% — addressing the cardiac lipidosis concerns identified in rodent studies of high-erucic-acid oils in the 1970s. Current canola oil meets FDA GRAS (Generally Recognized as Safe) status and EU food safety standards.

How to Use It

Use 1 tsp (5 mL) for cooking at higher temperatures where olive oil would degrade. Combining canola with extra-virgin olive oil across meals accesses both the MUFA/polyphenol profile of olive oil and the ALA omega-3 content of canola. Do not use for sustained deep frying — prolonged high heat generates oxidation products that negate the cardiovascular benefit.

What to Pair It With

Flavor Profile

Neutral, very mild, and nearly odorless when refined. Cold-pressed canola has a faint nutty note. Light-bodied with a high smoke point (~204°C), making it practical for sauteing where olive oil would burn.

The Science

• Gillingham et al., 2011, Br J Nutr: High-oleic rapeseed (canola) oil modulated serum lipids and reduced inflammatory biomarkers versus other dietary oils in a controlled trial.
• Bhatt et al., 2019, N Engl J Med: REDUCE-IT trial — omega-3 fatty acid (icosapent ethyl) supplementation reduced major cardiovascular events by 25% in high-risk patients, establishing marine and plant omega-3 intake as a credible CVD risk modifier.
• Micha et al., 2017, JAMA: Meta-analysis of dietary factors and US cardiovascular mortality — replacement of saturated with polyunsaturated fat among the strongest protective dietary patterns.
• Amiri et al., 2020, Nutr Metab Cardiovasc Dis: Meta-analysis of 42 RCTs — canola oil reduced LDL cholesterol by −0.23 mmol/L versus other oils; −0.49 mmol/L versus saturated fats; optimal effect at ~15% of total calories.
• Ghobadi et al., 2019, J Am Coll Nutr: Meta-analysis of 27 RCTs (1,359 participants) — canola oil reduced LDL by 6.4 mg/dL and total cholesterol by 7.24 mg/dL; greater effects in adults over 50 and with interventions exceeding 30 days.
• Naghshi et al., 2021, BMJ: Dose-response meta-analysis of 41 cohort studies (1,197,564 participants) — each 1 g/day increase in ALA associated with 5% lower CVD and all-cause mortality; higher ALA linked to 10% lower all-cause mortality and 8% lower CVD mortality.
• Jenkins et al., 2014, Diabetes Care: RCT in 141 type 2 diabetes patients — canola oil-enriched low-glycemic-load diet reduced HbA1c by −0.47% versus −0.31% in whole-grain control (P = 0.002), with greater Framingham CVD risk reduction.

References

1. Gillingham LG, Gustafson JA, Han SY, et al. High-oleic rapeseed (canola) and flaxseed oils modulate serum lipids and inflammatory biomarkers in hypercholesterolaemic subjects. Br J Nutr. 2011;105(3):417-427. PMID: 20875216. doi:10.1017/S0007114510003697
2. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. PMID: 30415628. doi:10.1056/NEJMoa1812792
3. Micha R, Penalvo JL, Cudhea F, et al. Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States. JAMA. 2017;317(9):912-924. PMID: 28267855. doi:10.1001/jama.2017.0947
4. Amiri M, Raeisi-Dehkordi H, Sarrafzadegan N, Forbes SC, Salehi-Abargouei A. The effects of Canola oil on cardiovascular risk factors: A systematic review and meta-analysis with dose-response analysis of controlled clinical trials. Nutr Metab Cardiovasc Dis. 2020;30(12):2133-2145. PMID: 33127255. doi:10.1016/j.numecd.2020.07.046
5. Ghobadi S, Hassanzadeh-Rostami Z, Mohammadian F, Zare M, Faghih S. Effects of Canola Oil Consumption on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. J Am Coll Nutr. 2019;38(2):185-196. PMID: 30381009. doi:10.1080/07315724.2018.1475270
6. Naghshi S, Aune D, Beyene J, et al. Dietary intake and biomarkers of alpha linolenic acid and risk of all cause, cardiovascular, and cancer mortality: systematic review and dose-response meta-analysis of cohort studies. BMJ. 2021;375:n2213. PMID: 34645650. doi:10.1136/bmj.n2213
7. Jenkins DJA, Kendall CWC, Vuksan V, et al. Effect of lowering the glycemic load with canola oil on glycemic control and cardiovascular risk factors: a randomized controlled trial. Diabetes Care. 2014;37(7):1806-1814. PMID: 24929428. doi:10.2337/dc13-2990

Key Nutrients